Psoriatic Arthritis Treatment Patterns and Costs Among Pharmacologic Treatment–Naïve Patients
We present results of an analysis of IBM MarketScan databases that evaluates treatment patterns and health care costs for treatment-naïve patients with psoriatic arthritis.
Cost of Biologic Treatment Persistence or Switching in Rheumatoid Arthritis
Patients with rheumatoid arthritis who switched biologics incurred higher costs than patients who persisted on biologics. Etanercept appeared to be associated with the lowest costs.
Two-Year Adherence and Costs for Biologic Therapy for Rheumatoid Arthritis
Adherence to newly initiated biologic therapy for rheumatoid arthritis is important for long-term adherence.
Disease-Modifying Antirheumatic Drug Initiation Among Patients Newly Diagnosed With Rheumatoid Arthritis
Only slightly more than half of patients with newly diagnosed rheumatoid arthritis initiated therapy within 1 year.
